For research and educational purposes only. Peptides are not approved for human use unless specifically indicated. Read full disclaimer.
PeptideHub
Benefits

AOD-9604 benefits: what the research shows

A concise, evidence-led summary of the effects AOD-9604 has been studied for — including where the data is strong, where it's preclinical, and what side effects have been reported.

Researched benefits of AOD-9604

  • Stimulation of lipolysis in adipose tissue without IGF-1 elevation
  • Reduced body fat accumulation in obese rodent models
  • No observed effect on blood glucose or insulin sensitivity at studied doses
  • Potential cartilage repair signaling noted in preclinical arthritis models
  • Favorable safety profile in Phase II human obesity trials

How AOD-9604 produces these effects

AOD-9604 is thought to bind a truncated or isoform variant of the GH receptor, activating beta-3 adrenergic receptor-like pathways that stimulate lipolysis (fat cell breakdown) and inhibit lipogenesis (new fat formation). Crucially, it does not appear to activate the IGF-1 pathway or stimulate general tissue growth.

What AOD-9604 is not studied for

It is important to distinguish researched effects from extrapolations. Most AOD-9604 data comes from cell and animal models. Human use is typically observational. AOD-9604 is not a replacement for medical care or a prescription medication unless specifically indicated.

Side effects & limitations

  • Mild injection-site reactions (redness, transient discomfort)
  • Occasional headache reported in clinical trial participants
  • Nausea in a small percentage of subjects at higher doses

Selected literature

  • AOD9604: An anti-obesity drug which stimulates fat metabolism without affecting muscle or bone in obese dogs — Endocrine, 2001
  • A lipolytic fragment of human growth hormone reduces adiposity in obese mice — Journal of Endocrinology, 2000
  • Safety and tolerability of AOD9604 in healthy adult subjects — Journal of Endocrinology and Metabolism, 2004

Get the full AOD-9604 research dossier

Subscribe for our weekly research digest. New AOD-9604 studies, dosing updates, and curated industry deals.

Get peptide calculators, research updates, and practical education in your inbox. No spam, unsubscribe in one click.

← AOD-9604 overviewAOD-9604 dosage →AOD-9604 stacks →

AOD-9604 benefits FAQ

What are the main benefits of AOD-9604?+

In research, AOD-9604 has been studied for: stimulation of lipolysis in adipose tissue without igf-1 elevation; reduced body fat accumulation in obese rodent models; no observed effect on blood glucose or insulin sensitivity at studied doses. Effects in humans depend on dose, route, and protocol.

How does AOD-9604 work?+

AOD-9604 is thought to bind a truncated or isoform variant of the GH receptor, activating beta-3 adrenergic receptor-like pathways that stimulate lipolysis (fat cell breakdown) and inhibit lipogenesis (new fat formation). Crucially, it does not appear to activate the IGF-1 pathway or stimulate general tissue growth.

How long until AOD-9604 benefits appear?+

Most reported benefits in AOD-9604 research emerge within 2–4 weeks of consistent administration. Tissue-remodeling endpoints (e.g., tendon healing, skin firmness) typically appear later than acute signaling effects (e.g., GH pulse, appetite suppression).

Is AOD-9604 safe?+

AOD-9604 has the following commonly reported side effects: Mild injection-site reactions (redness, transient discomfort); Occasional headache reported in clinical trial participants; Nausea in a small percentage of subjects at higher doses. Most peptides lack large-scale long-term human safety data. This is not medical advice.